Berubicin hydrochloride

DRUG4 trials

Sponsors

Pomeranian Medical University, Cns Pharmaceuticals Inc., WPD Pharmaceuticals Sp. z o.o.

Conditions

Glioblastoma multiforme (GBM)High Grade GliomaRecurrent Glioblastoma Multiformecentral nervous system (CNS) lymphomas

Phase 1

Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

TerminatedNCT04915404

WPD Pharmaceuticals Sp. z o.o.Recurrent Glioblastoma Multiforme

Start: 2022-12-07End: 2023-12-30Updated: 2024-06-06

A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

WithdrawnNCT05082493

WPD Pharmaceuticals Sp. z o.o.High Grade Glioma

Start: 2023-12-31End: 2023-12-30Updated: 2024-06-06

Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN

Not yet recruitingCTIS2024-516773-69-00

Pomeranian Medical Universitycentral nervous system (CNS) lymphomas

Target: 60Updated: 2024-11-18

Phase 2

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Active, not recruitingCTIS2024-517660-27-00

Cns Pharmaceuticals Inc.Glioblastoma multiforme (GBM)

Start: 2022-09-22Target: 126Updated: 2025-12-23